Galderma rises after Q1 sales beat

Galderma AG

23/04/2026 08:44

** Shares in Switzerland's Galderma GALD.S are up around 5% after the skincare firm reported Q1 sales above expectations

** The company reported sales at 1.5 billion dollars, above an LSEG consensus of 1.47 billion and up around 25.5% on a constant currency basis compared to the previous year

** Vontobel says that the beat was driven by positive price effects, adding that starting in Q2, higher volumes should follow for Nemluvio in the U.S.

** The broker says the U.S. is expected to approve skin wrinkle reducing drug Relfydess later in the year, supporting growth in H2 and beyond

 (Reporting by Cian Muenster)

 ((Cian.muenster@thomsonreuters.com))